&l;p&g;&l;img class=&q;size-large wp-image-17&q; src=&q;http://blogs-images.forbes.com/rcarson/files/2018/04/GettyImages-688949102-1200×701.jpg?width=960&q; alt=&q;&q; data-height=&q;701&q; data-width=&q;1200&q;&g; Ask yourself: Am I&a;nbsp;financially prepared for retirement?
Becoming a first-time grandfather makes one acutely aware of the number of years left on this planet. Suddenly,....More>>>
Yesterday, our Under the Radar Moversnewsletter suggested small cap clinical-stage biotech RXi Pharmaceuticals Corp (NASDAQ: RXII) as a long/bullish trade for our short-term portfolio:
RXi Pharmaceuticals was hit pretty hard in September and October, but we like the way the stock’s been piecing together the foundation for a technical breakout. That is, we’ve made a higher low,....More>>>
I have written about Global Blood Therapeutics (NASDAQ:GBT) before here. In my prior article, I addressed a number of fairly legitimate concerns people have cited about the stock and its lead drug for sickle cell disease (“SCD”) called GBT-440, and I explained how those risks are less significant than one might believe, or are being successfully mitigated by the company.
Ever since Warren Buffett has brought in Tedd Combs and Todd Weschler, investors were looking for signs of change, if any, in Berkshire’s approach to investing. And after a few years’ wait, the signs of change are appearing.In last few months, Berkshire has made acouple of investments which took the market by surprise. The first one was theinvestment in the technology giantApple (NSDQ:AAPL)....More>>>
Takeda Pharmaceutical Co. is nearing a preliminary agreement to acquire Shire Plc after the Japanese drugmaker sweetened its roughly $60 billion bid for the biotechnology company, according to people with knowledge of the matter.
Shire’s board “is considering its position” on a new bid, the company said in a statement Tuesday after Bloomberg News reported that the companies....More>>>